FASS - Fast and Accurate Solubility for Sustainability
Bring to the market a revolutionary laboratory instrument for the measurement of the solubility of drug substance.
PHARMACEUTICAL STAKES
Bringing a drug to market is a relatively long process, lasting around ten years. It is particularly costly, approximately several billion euros, and requires numerous tests on solubility and dissolution. Indeed, 40% of drugs are poorly soluble, and poorly absorbed, with adverse properties leading to loss of efficacy and undesirable immune responses. Measuring solubility is a physico-chemical problem, and the pharmaceutical industry, despite possessing complex technologies, has no revolutionary and sustainable solution to date. Consequently, checking a drug's solubility is crucial, not only for its efficacy but also for the investment it entails.
FOR MORE EFFECTIVE, MORE ECONOMIC AND MORE ECOLOGICAL MEDICINES
The FASS (Fass and Accurate Solubility for Sustainability) collaborative project, aims to bring to the market a revolutionary laboratory instrument to measure the solubility of drug molecules. A solution that's both innovative and sustainable, thanks to lower consumption of chemicals, electricity and consumables, while achieving peak performance in terms of sensitivity and reliability.
In order to develop effective drugs, laser technology, in particular through fast, sensitive and precise light scattering, fills the gaps in solubility measurement. It is based on the 'Solvent Redistribution' method - born at EPFL - which is the world's first solution that will disrupt way solubility measurement is performed.
"This grant will accelerate the development and market entry of our laboratory instrument. Oryl Photonics is excited to make a world impact through its light-scattering based technology that fills a gap in the market offering of solubility measurement. The output of the grant will empower researchers in the pharmaceutical, chemical and life sciences industries to achieve more in their work, with sustainability and performance in mind." Orly Tarun, CEO and Co-founder of Oryl Photonics.
ALPhANOV's ROLE
To accelerate the development of the instrument, ALPhANOV is helping with the 3D designs, electronics and optical simulations to improve and optimize the instrument. The center's expertise will bring the technology all the way to a pre-industrialization level, right before mass production.
Laboratory instruments development
A driver of innovation, photonics has already proved its worth in the healthcare sector, particularly in imaging, surgery, ophthalmology... Today, it promises to put its potential at the service of pharmacology.
THE PARTNERS
The FASS project consortium is led by EU-Openscreen as coordinator and includes Oryl Photonics, FHNW and ALPhANOV. The consortium composition is optimal to achieve the project's objective, with complementary expertise in photonics and laser technologies, drug screening and discovery, and pharmaceutical formulation.
THE FUNDERS
Project starting date : 06/01/24